Visiongain

02/10/2026

The US is moving to put autonomous warfare and industrial resilience on a more permanent footing.

A proposed four-star Autonomous Warfare Command, FORTRESS America and Project Meridian could reshape procurement, supply chains and future capability development.

Our latest Visiongain Market Watch: Aerospace, Defence & Security examines what is changing, where demand could emerge, and which initiatives are most likely to matter commercially.

Read the full analysis: https://visiongain.com/us-defence-accelerates-autonomy-and-resilience/

US defence links autonomy, resilience and procurement in major reforms

01/10/2026

What should pharma be watching at CPHI Milan 2026?

Supply resilience, specialist manufacturing capacity and AI are changing the calculations around where pharma companies manufacture, outsource and invest.

Three questions stand out:

• How much resilience is worth paying for?

• Which AI technologies are ready for regulated production?

• Where is the right manufacturing capacity becoming harder to secure?

This week’s Visiongain Market Watch: Healthcare, Pharma & Biotech examines what to watch as CPHI Milan opens next week, and what it could mean for manufacturing strategy beyond the event.

Read the full analysis: https://visiongain.com/cphi-milan-2026-three-manufacturing-questions-were-watching/

CPHI Milan opens next week with manufacturing under growing scrutiny across the pharmaceutical industry

25/09/2026

Britain is reshaping battlefield reconnaissance around a mix of long-endurance and frontline drones.

TEKEVER’s AR5 will replace Watchkeeper in the long-range ISR role, while 1,025 smaller drones are being delivered for frontline reconnaissance.

Their operational value will depend on how well they fit into the Army’s Recce Strike model, linking surveillance more closely to targeting and long-range fires.

This week’s Market Watch: Aerospace, Defence & Security looks at the role of Project Asgard, the push to speed up drone procurement, and why TEKEVER is bringing core AR5 production to Britain.

Read the full analysis: https://visiongain.com/britains-recce-strike-drone-fleet-takes-shape/

Britain reshapes battlefield reconnaissance with AR5 and smaller tactical drones

24/09/2026

The US Army is replacing legacy tactical networks.

Its new command-and-control baseline combines multi-orbit SATCOM, automated routing, tactical edge computing and commercial technology.

Visiongain forecasts the Military Communications & COTS market to grow from US$42.90bn in 2026 to US$75.70bn by 2036.

See where demand is emerging and how procurement requirements are changing:

Explore the report: https://visiongain.com/report/military-communications-market-2026/

23/09/2026

Clinical trials are becoming harder to run behind the scenes.

Recent developments from DHL, UPS, THREAD and the U.S. Food and Drug Administration show where some of the pressure is building, from cold-chain hand-offs and fragmented trial data to getting sites and supporting systems ready sooner.

Visiongain values the global Clinical Trial Supply and Logistics Market for Pharma at US$7.92bn in 2026, rising to US$18.22bn by 2036 at a CAGR of 8.7%.

In our latest Market Watch: Healthcare, Pharma & Biotech, we look at where providers are investing, how trial infrastructure is changing and what this could mean for sponsors and CROs.

Read the full analysis: https://visiongain.com/clinical-trial-infrastructure-moves-centre-stage/

Clinical trials are getting harder to run as complexity increases

17/09/2026

Europe could need around 35,000 publicly accessible MCS charging points by 2030.

Megawatt charging is moving into commercial deployment, but scaling the network will depend on more than charger rollout. Grid capacity, site access and energy management could all affect how quickly high-power charging expands.

Visiongain forecasts the EV charging infrastructure market to reach US$166.36bn by 2036, up from US$43.70bn in 2026 at a CAGR of 14.3%.

Our latest report examines where demand is growing fastest, what could constrain deployment and where opportunities are developing across charging infrastructure, software and energy services.

Get sample pages: https://visiongain.com/report/ev-charging-infrastructure-market-2026/

16/09/2026

Not all pharma manufacturing capacity is equally usable.

Sterile fill-finish and advanced therapies show why shortages and underused facilities can exist at the same time.

This week in Market Watch: Healthcare, Pharma & Biotech, we look at why specialist capacity takes time to bring online, how product format narrows manufacturing options, and why advanced-therapy capacity can be highly programme-specific.

Featuring: Genentech, Northway Biotech, Bristol Myers Squibb

Read the full article: https://visiongain.com/pharmas-capacity-illusion/

11/09/2026

Small drones are getting cheaper, harder to disrupt and easier to field at scale.

New US guidance shows why counter-UAS is no longer just about shooting drones down. Detection, disruption, passive protection and lower-cost interception all matter when attacks come in numbers.

In the latest Market Watch: Aerospace, Defence & Security, we look at the changing economics of drone defence, the US Army’s 13,000-drone Merops purchase, and why the decision chain behind sensors and effectors can be just as important as the hardware itself.

Featuring: U.S. Army, U.S. Department of War, Air Combat Command

Read the full article: https://visiongain.com/small-drones-force-a-rethink-of-counter-uas-defence/

Small drones are reshaping defence through layered, affordable counter-UAS strategies

09/09/2026

A CDMO contract win can still be years away from commercial revenue.

Our latest Market Watch looks at how site transfers, technology transfer and programme stage are shaping the value of pharmaceutical manufacturing partnerships.

Featuring: Lifecore Biomedical, Hovione, Genprex, Inc., Andelyn Biosciences.

Read the analysis: https://visiongain.com/pharmas-manufacturing-reshuffle-is-feeding-cdmo-growth/

Commercial site transfers reshape CDMO growth, revenue timing and value

18/08/2026

The next bottleneck in US weapons production may sit further upstream, in the batteries, bauxite and magnets that modern systems depend on.

In the latest Visiongain Market Watch: Aerospace, Defence & Security, we examine how Washington is using government capital, regional supply chains and alternative technologies to reduce critical-material dependencies.

Featuring: U.S. Department of War, Sila Nano, First Bauxite Inc.

Read the full analysis: https://visiongain.com/why-batteries-bauxite-and-magnets-are-becoming-defence-priorities/

Washington targets critical material dependencies across batteries, bauxite and magnets